Gadicke Ansbert: insider trades.
Gadicke Ansbert reported 12 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 12 sales ($3.6M), across 1 company.
- Transactions
- 12
- Purchases (P)
- 0
- Sales (S)
- 12
- Companies
- 1
- Name as filed
- GADICKE ANSBERT
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | TenPercentOwner | 12 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-09 | Entrada Therapeutics, Inc. | S | 28,837 | $7.13 | 3,885,115 | Form 4 |
| 2026-09-08 | Entrada Therapeutics, Inc. | S | 192,500 | $7.41 | 3,913,952 | Form 4 |
| 2026-09-04 | Entrada Therapeutics, Inc. | S | 38,500 | $7.11 | 4,106,452 | Form 4 |
| 2026-09-03 | Entrada Therapeutics, Inc. | S | 32,263 | $7.17 | 4,144,952 | Form 4 |
| 2026-09-02 | Entrada Therapeutics, Inc. | S | 25,131 | $7.19 | 4,177,215 | Form 4 |
| 2026-09-01 | Entrada Therapeutics, Inc. | S | 29,088 | $7.06 | 4,202,346 | Form 4 |
| 2026-08-31 | Entrada Therapeutics, Inc. | S | 44,259 | $6.99 | 4,231,434 | Form 4 |
| 2026-08-28 | Entrada Therapeutics, Inc. | S | 3,733 | $7.01 | 4,275,693 | Form 4 |
| 2026-08-27 | Entrada Therapeutics, Inc. | S | 38,922 | $7.2 | 4,279,426 | Form 4 |
| 2026-08-26 | Entrada Therapeutics, Inc. | S | 14,569 | $7.06 | 4,318,348 | Form 4 |
| 2026-08-25 | Entrada Therapeutics, Inc. | S | 26,522 | $7.54 | 4,332,917 | Form 4 |
| 2026-08-24 | Entrada Therapeutics, Inc. | S | 21,623 | $7.34 | 4,359,439 | Form 4 |
Questions
What stock did Gadicke Ansbert buy or sell?
Gadicke Ansbert reported 12 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 12 sales ($3.6M), across 1 company.
Is Gadicke Ansbert the same person as other filers with this name?
This page covers SEC CIK 1134655 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/gadicke-ansbert-1134655.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.